DJIA 17,387.21 -291.49 -1.65%
NASDAQ 4,681.50 -90.27 -1.89%
S&P 500 2,029.55 -27.54 -1.34%
market minute promo

2.10 0.10 (5.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

PLX $2.10 5.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.01
Previous Close $2.00
Daily Range $2.00 - $2.13
52-Week Range $1.71 - $5.30
Market Cap $196.7M
P/E Ratio 8.00
Dividend (Yield) $0.00 (0.0%)
Volume 81,086
Average Daily Volume 332,484
Current FY EPS -$0.27





Protalix BioTherapeutics, Inc. (PLX) Description

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system. Website:

News & Commentary Rss Feed

3 High-Risk, High-Reward Biotech Stocks for Long Term Investors

Everyone wants to get rich, but investing in the wrong developmental companies can have disastrous consequences. Here are three companies with game-changing potential that have yet to hit their stride -- and may payoff in the long run.

Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning

Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Rises 16% - Tale of the Tape

Health Care Sector Update for 01/05/2015: PLX,CNAT,BCLI

Monday Sector Leaders: Biotechnology, Drugs

Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher

5 Stocks Ready to Break Out and Soar Higher

Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape

How Protalix BioTherapeutics (PLX) Stock Stands Out in a Strong Industry - Tale of the Tape

How Protalix BioTherapeutics (PLX) Stock Stands Out in a Strong Industry - Tale of the Tape

Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog

See More PLX News...

PLX's Top Competitors

PLX $2.10 (5.00%)
Current stock: PLX
AMGN $158.42 (-0.82%)
Current stock: AMGN
GILD $105.03 (-1.94%)
Current stock: GILD
BIIB $358.23 (-1.16%)
Current stock: BIIB